首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   11811篇
  免费   726篇
  国内免费   64篇
耳鼻咽喉   117篇
儿科学   318篇
妇产科学   241篇
基础医学   1693篇
口腔科学   255篇
临床医学   1044篇
内科学   2703篇
皮肤病学   424篇
神经病学   1183篇
特种医学   268篇
外科学   982篇
综合类   58篇
现状与发展   1篇
一般理论   3篇
预防医学   1399篇
眼科学   276篇
药学   799篇
中国医学   52篇
肿瘤学   785篇
  2024年   11篇
  2023年   140篇
  2022年   275篇
  2021年   508篇
  2020年   262篇
  2019年   432篇
  2018年   524篇
  2017年   316篇
  2016年   308篇
  2015年   382篇
  2014年   532篇
  2013年   650篇
  2012年   1004篇
  2011年   956篇
  2010年   559篇
  2009年   465篇
  2008年   737篇
  2007年   731篇
  2006年   619篇
  2005年   660篇
  2004年   578篇
  2003年   529篇
  2002年   476篇
  2001年   92篇
  2000年   55篇
  1999年   94篇
  1998年   79篇
  1997年   66篇
  1996年   64篇
  1995年   51篇
  1994年   32篇
  1993年   39篇
  1992年   33篇
  1991年   29篇
  1990年   23篇
  1989年   15篇
  1988年   19篇
  1987年   18篇
  1986年   11篇
  1985年   17篇
  1984年   21篇
  1983年   25篇
  1982年   8篇
  1981年   15篇
  1980年   11篇
  1979年   14篇
  1978年   11篇
  1977年   10篇
  1974年   11篇
  1968年   8篇
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
4.
5.
6.
7.
Purpose:  To evaluate all consecutive patients treated with infliximab for hidradenitis suppurativa (HS).
Patients and methods:  Within 1 year, all consecutive patients seen in our department for HS (1) resistant to usual medical therapies (2) which could not be easily cured by surgery (3) not treated with new medication within 2 months before inclusion were treated intravenously with infliximab (5 mg/kg) without corticosteroids premedication. Four infusions were planned (week 0, week 2, week 6 and week 10) before the interruption of therapy and follow-up. Clinical activity of HS and quality of life of the patients were assessed immediately before the first, the third and the fourth infusions of infliximab.
Results:  Seven patients were included. Five completed the four infusions. Two patients received only three infusions because of severe side effects. The Sartorius score moderately improved with infliximab (mean score at week 0: 94 ± 39, at week 6: 71 ± 38 and at week 10: 83 ± 48). At week 6, patients judged the efficacy of therapy as marked ( n  = 1), moderate ( n  = 4) or null ( n  = 2). At week 10, five patients were evaluated and judged this efficacy as marked ( n  = 2), moderate ( n  = 2) or null ( n  = 1). The mean Skindex-29 score varied from 22 ± 11 (E: 25 ± 9, S: 13 ± 5, F: 28 ± 12) at week 0 to 18 ± 10 (E: 22 ± 8, S: 12 ± 8, F: 22 ± 12) at week 10.
Conclusion:  The efficacy of infliximab in severe HS is partial. More experience is needed before finding a place for infliximab in the therapeutic armamentarium for HS.  相似文献   
8.
9.
ObjectiveWe examine remission rate probabilities, recovery rates, and residual symptoms across 36 weeks in the Treatment for Adolescents with Depression Study (TADS).MethodThe TADS, a multisite clinical trial, randomized 439 adolescents with major depressive disorder to 12 weeks of treatment with fluoxetine, cognitive–behavioral therapy, their combination, or pill placebo. The pill placebo group, treated openly after week 12, was not included in the subsequent analyses. Treatment differences in remission rates and probabilities of remission over time are compared. Recovery rates in remitters at weeks 12 (acute phase remitters) and 18 (continuation phase remitters) are summarized. We also examined whether residual symptoms at the end of 12 weeks of acute treatment predicted later remission.ResultsAt week 36, the estimated remission rates for intention-to-treat cases were as follows: combination, 60%; fluoxetine, 55%; cognitive–behavioral therapy, 64%; and overall, 60%. Paired comparisons reveal that, at week 24, all active treatments converge on remission outcomes. The recovery rate at week 36 was 65% for acute phase remitters and 71% for continuation phase remitters, with no significant between-treatment differences in recovery rates. Residual symptoms at the end of acute treatment predicted failure to achieve remission at weeks 18 and 36.ConclusionsMost depressed adolescents in all three treatment modalities achieved remission at the end of 9 months of treatment.  相似文献   
10.
We review the association between surgically resolvable aortic disease and horseshoe kidney with a discussion of diagnostic problems and therapeutic options.Male patient 81 years of age with horseshoe kidney and an abdominal aortic aneurysm that was discovered by chance in an abdominal ultrasound during a check-up for his prostate condition.A retroperitoneal approach was used in order to resect the aneurysm and perform an aorto-aortic bypass with no complications occurring. Two years after the diagnosis, the patient is still asymptomatic from a vascular point of view.The co-presence of horseshoe kidney and aortic disease needing surgical correction is infrequent, but it significantly increases the technical complexity of aortic reconstruction. A literature review is included.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号